Back to today’s briefing

Story perspectives

Immunotherapy Timing and Dosing Transform Lung Cancer Outcomes

12/12/2025

46 6 Full Breakdown

Summary

Story summary

Lung cancer patients who receive intravenous immunotherapy before 3 p.m. show a 52% lower risk of progression and a 63% lower risk of death.
The findings could inform treatment protocols for lung cancer.
In melanoma, lower immunotherapy doses are associated with better outcomes and fewer side effects.
Patients on a flipped dose regimen achieved a 49% response rate and longer progression-free survival than those on standard doses.

1 of 1

Story summary

Lung cancer patients who receive intravenous immunotherapy before 3 p.m. show a 52% lower risk of progression and a 63% lower risk of death.
The findings could inform treatment protocols for lung cancer.
In melanoma, lower immunotherapy doses are associated with better outcomes and fewer side effects.
Patients on a flipped dose regimen achieved a 49% response rate and longer progression-free survival than those on standard doses.